glp 1 eating disorder 504: Adult Disorders in the GLP-1 Era The Ozempic Era and Eating

Risk differences were attenuated among metformin monotherapy users (2.0 and 4.1) compared with users of 2 or more diabetes medications (5.7 and 4.0) versus SGLT2is and DPP4is, respectively

L-carnitine requires more form selection

A compound with limited human data, an unresolved safety history, and no approval isby definitionnot a validated therapy

* Correspondence: Michele Ghidini, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

The researchers focused on a class of drugs called GLP-1 receptor agonists